Last updated on July 2018

Effect of Entecavir Treatment on Regression and Disease Outcome in HBV-induced Liver Fibrosis and Cirrhosis Patients

Brief description of study

Patients who have completed 2-years entecavir-based treatment in Regress Study will receive another 5-years entecavir extension therapy. Patients will be assessed at baseline and every six months for blood cell count, liver function test, HBVDNA, AFP, prothrombin time, liver ultrasonography, and Fibroscan; A third liver biopsy will be performed at year 3 in patients who have significant fibrosis at second biopsy. CT and endoscopy will be performed at baseline and year 3.

Clinical Study Identifier: NCT02849132

Find a site near you

Start Over